Roche Holdings Ltd ADR (RHHBY)

$57.11 -0.59 (-1.02%)
Market Cap 367.58B
Revenue (ttm) 76.45B
Net Income (ttm) 15.54B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 18.12
Profit Margin 20.33%
Debt to Equity Ratio 1.00
Volume 3,509,200
Avg Vol 2,766,894
Day's Range N/A - N/A
Shares Out 6.37B
Stochastic %K 76%
Beta 0.44
Analysts Sell
Price Target $52.72

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
scotttrader213
scotttrader213 Apr. 23 at 3:40 PM
$RHHBY Many of Roche’s biggest drugs come from Genentech pipelines * Roughly a huge portion of Roche’s pharma innovation flows through Genentech * Genentech is a core competitive advantage vs other pharma giants
1 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 22 at 2:02 PM
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition $OTLC $AUTL $WVE $IOBTQ $RHHBY https://ibn.fm/4yuU5
0 · Reply
stu
stu Apr. 22 at 1:14 PM
$TGTX $RHHBY Fenebrutinib and deaths: "AAN26: Relapse rates for Roche's MS drug fenebrutinib overshadowed by lingering safety concerns." "Roche presented further positive efficacy results on its multiple sclerosis (MS) therapy hopeful fenebrutinib at the American Academy of Neurology (AAN) annual meeting on Tuesday, but the BTK inhibitor's safety profile remains a key focus, particularly an imbalance in deaths." " Data showed that the deaths occurred at different timepoints and had various causes, including infections — neuro Cryptococcosis gattii and pneumonia — complications of type 1 diabetes, serious bleeding, suicide, injuries from accident and death of unknown cause." https://firstwordpharma.com/story/7203815
2 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker Apr. 22 at 12:21 AM
$KYTX x $RHHBY = EU GTM rocket 🚀 👉 Roche is a top-5 global pharma + oncology KING with unmatched reach 👉 Deep oncology + cell therapy focus = perfect fit for Kyverna pipeline 👉 150+ markets + global commercial engine ready to scale instantly 👉 Unique combo of diagnostics + pharma = precision medicine advantage (huge for autoimmune positioning) 👉 Proven partner mindset (BioNTech, MOMA, Chugai… they know how to scale biotech) 💡 Translation: Roche doesn’t just partner… they industrialize innovation globally If $KYTX wants serious EU GTM + credibility with payers & regulators…this is the Tier 1 door. Big pharma validation + EU scale = rerating catalyst 💲💲💲
0 · Reply
Thaigrlsrk
Thaigrlsrk Apr. 19 at 12:54 AM
$SRPT Jack Hall @Hall8Jack · Apr 17 I read the primary endpoint for this new $RHHBY trial is TTR instead of NSAA. If so, this seems like favorable treatment by the EMA. $SRPT Embark was stat sig on TTR. https://fiercepharma.com/pharma/roche-launch-another-elevidys-study-after-eu-rejection-duchenne-gene-therapy .
1 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker Apr. 17 at 4:15 PM
$KYTX $GILD $KITE $BMY $RHHBY who will make the MOVE first? And who will be the last to join the party below 10$? Good Luck Ladies and Gentlemen 💲 💲💲
0 · Reply
IndyOne
IndyOne Apr. 16 at 4:45 PM
$MRNA Moderna is an absolute work horse. V940 clinical results for Melanoma and NSCLC (Non-Small Cell Lung Cancer). V940 platform expansion includes renal cell carcinoma and bladder cancer. CEO committed to 10%+ revenue growth 2026. TELLS: October 2025: "Deal of significant scope" in discussion, buyout or massive partnership. December 2025: Stéphane Bancel, Moderna CEO, sold his six-level home in Boston where he had lived for +12 years. January 2026: Moderna and Merck announced V940 results showed a 49% reduction in the risk of recurrence or death. Keytruda goes off patent soon, Merck can use Moderna's mRNA-4157 (also known as intismeran autogene) a first-of-its-kind, personalized mRNA cancer vaccine to extend Keytruda protection. February 2026: Patent litigation resolved. NO ROYALTIES! HUGE WIN. Moderna wanted the decks clear, they could have fought this longer like Pfizer & BioNtech. Partnership or buyout coming from $MRK $PFE $RHHBY or $GSK .
0 · Reply
scotttrader213
scotttrader213 Apr. 16 at 3:05 PM
$RHHBY announced on Thursday that it is initiating a new Phase 3 trial for Elevidys, a treatment it developed with Sarepta Therapeutics $SRPT for the muscle-wasting disorder. Duchenne muscular dystrophy, in an attempt to secure EU approval for the gene therapy.
1 · Reply
scotttrader213
scotttrader213 Apr. 15 at 12:54 PM
$RHHBY C4 Therapeutics $CCCC to receive $20M from Roche (RHHBY) for the two programs, with an additional payment due if the Swiss drugmaker exercises its option for a third program.
0 · Reply
Quantumup
Quantumup Apr. 15 at 11:19 AM
Mizuho🏁 $CLYM Outperform; $18 $RHHBY $BIIB VRTX GSK Mizuho said: We are initiating coverage of Climb Bio with an Outperform rating and $18 price target, as we see its lead assets budoprutug (anti-CD19 mAb) and CLYM116 (anti-APRIL mAb) as positioned to establish a compelling B-cell targeting pipeline with best-in-indication profiles in autoimmune nephropathies. Specifically, we believe additional updates for budoprutug in primary membranous nephropathy (pMN) in 2H26 and initial data for CLYM116 in healthy volunteers (HVs) in mid-2026 have the opportunity to provide data points that will validate potential to drive the deepest reductions in proteinuria within their competitive landscapes. As we exit 2026, budoprutug and CLYM116 could be positioned for registrational development across two blockbuster opportunities that we believe could support ~$600M in risk-adjusted WW sales by 2035.
0 · Reply
Latest News on RHHBY
No data available.
scotttrader213
scotttrader213 Apr. 23 at 3:40 PM
$RHHBY Many of Roche’s biggest drugs come from Genentech pipelines * Roughly a huge portion of Roche’s pharma innovation flows through Genentech * Genentech is a core competitive advantage vs other pharma giants
1 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 22 at 2:02 PM
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition $OTLC $AUTL $WVE $IOBTQ $RHHBY https://ibn.fm/4yuU5
0 · Reply
stu
stu Apr. 22 at 1:14 PM
$TGTX $RHHBY Fenebrutinib and deaths: "AAN26: Relapse rates for Roche's MS drug fenebrutinib overshadowed by lingering safety concerns." "Roche presented further positive efficacy results on its multiple sclerosis (MS) therapy hopeful fenebrutinib at the American Academy of Neurology (AAN) annual meeting on Tuesday, but the BTK inhibitor's safety profile remains a key focus, particularly an imbalance in deaths." " Data showed that the deaths occurred at different timepoints and had various causes, including infections — neuro Cryptococcosis gattii and pneumonia — complications of type 1 diabetes, serious bleeding, suicide, injuries from accident and death of unknown cause." https://firstwordpharma.com/story/7203815
2 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker Apr. 22 at 12:21 AM
$KYTX x $RHHBY = EU GTM rocket 🚀 👉 Roche is a top-5 global pharma + oncology KING with unmatched reach 👉 Deep oncology + cell therapy focus = perfect fit for Kyverna pipeline 👉 150+ markets + global commercial engine ready to scale instantly 👉 Unique combo of diagnostics + pharma = precision medicine advantage (huge for autoimmune positioning) 👉 Proven partner mindset (BioNTech, MOMA, Chugai… they know how to scale biotech) 💡 Translation: Roche doesn’t just partner… they industrialize innovation globally If $KYTX wants serious EU GTM + credibility with payers & regulators…this is the Tier 1 door. Big pharma validation + EU scale = rerating catalyst 💲💲💲
0 · Reply
Thaigrlsrk
Thaigrlsrk Apr. 19 at 12:54 AM
$SRPT Jack Hall @Hall8Jack · Apr 17 I read the primary endpoint for this new $RHHBY trial is TTR instead of NSAA. If so, this seems like favorable treatment by the EMA. $SRPT Embark was stat sig on TTR. https://fiercepharma.com/pharma/roche-launch-another-elevidys-study-after-eu-rejection-duchenne-gene-therapy .
1 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker Apr. 17 at 4:15 PM
$KYTX $GILD $KITE $BMY $RHHBY who will make the MOVE first? And who will be the last to join the party below 10$? Good Luck Ladies and Gentlemen 💲 💲💲
0 · Reply
IndyOne
IndyOne Apr. 16 at 4:45 PM
$MRNA Moderna is an absolute work horse. V940 clinical results for Melanoma and NSCLC (Non-Small Cell Lung Cancer). V940 platform expansion includes renal cell carcinoma and bladder cancer. CEO committed to 10%+ revenue growth 2026. TELLS: October 2025: "Deal of significant scope" in discussion, buyout or massive partnership. December 2025: Stéphane Bancel, Moderna CEO, sold his six-level home in Boston where he had lived for +12 years. January 2026: Moderna and Merck announced V940 results showed a 49% reduction in the risk of recurrence or death. Keytruda goes off patent soon, Merck can use Moderna's mRNA-4157 (also known as intismeran autogene) a first-of-its-kind, personalized mRNA cancer vaccine to extend Keytruda protection. February 2026: Patent litigation resolved. NO ROYALTIES! HUGE WIN. Moderna wanted the decks clear, they could have fought this longer like Pfizer & BioNtech. Partnership or buyout coming from $MRK $PFE $RHHBY or $GSK .
0 · Reply
scotttrader213
scotttrader213 Apr. 16 at 3:05 PM
$RHHBY announced on Thursday that it is initiating a new Phase 3 trial for Elevidys, a treatment it developed with Sarepta Therapeutics $SRPT for the muscle-wasting disorder. Duchenne muscular dystrophy, in an attempt to secure EU approval for the gene therapy.
1 · Reply
scotttrader213
scotttrader213 Apr. 15 at 12:54 PM
$RHHBY C4 Therapeutics $CCCC to receive $20M from Roche (RHHBY) for the two programs, with an additional payment due if the Swiss drugmaker exercises its option for a third program.
0 · Reply
Quantumup
Quantumup Apr. 15 at 11:19 AM
Mizuho🏁 $CLYM Outperform; $18 $RHHBY $BIIB VRTX GSK Mizuho said: We are initiating coverage of Climb Bio with an Outperform rating and $18 price target, as we see its lead assets budoprutug (anti-CD19 mAb) and CLYM116 (anti-APRIL mAb) as positioned to establish a compelling B-cell targeting pipeline with best-in-indication profiles in autoimmune nephropathies. Specifically, we believe additional updates for budoprutug in primary membranous nephropathy (pMN) in 2H26 and initial data for CLYM116 in healthy volunteers (HVs) in mid-2026 have the opportunity to provide data points that will validate potential to drive the deepest reductions in proteinuria within their competitive landscapes. As we exit 2026, budoprutug and CLYM116 could be positioned for registrational development across two blockbuster opportunities that we believe could support ~$600M in risk-adjusted WW sales by 2035.
0 · Reply
LabPsycho
LabPsycho Apr. 14 at 5:10 PM
$RHHBY This is Pure hypothetical pseudo science speculation here and for artistic and self amusement purposes only: I think it could be possible to potentially form an Anti-PD-L1-6-thio-2'-deoxyguanosine antibody drug conjugate - in situ ! Using MAIA THIO drug (started phase 3 for lung cancer) to potentially help efficacy and lower side effects. By parlaying the activity of endogenous protein disulfide isomerases in the serum to catalyze (link) THIO to the antibody. Let the body do the work for you so no need to file IND - Ha. The Antibody combined with Thio (all in the same IV bag) could slowly infused (high concentrations of both 'reactants' as they enter the blood, then poof, InstaConjugate (TM)! If that doesnt work one could always blast some UV light into the IV bag.
0 · Reply
LibertarianTreehugger
LibertarianTreehugger Apr. 14 at 1:53 PM
A Simple Blood Draw Could Replace Guesswork in Multiple Sclerosis: https://jlsfund.substack.com/p/a-simple-blood-draw-could-replace $RHHBY
0 · Reply
briefingcom
briefingcom Apr. 13 at 12:41 PM
$RHHBY: Roche Hldg receives CE mark for MS blood test, expanding neuro diagnostics portfolio https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260413044753RHHBY&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
StocktwitsNews
StocktwitsNews Apr. 9 at 12:08 PM
CCCC Stock Gets Pre-Market Boost On Roche Tie-Up To Develop Cancer Treatments $CCCC $RHHBY https://stocktwits.com/news/equity/markets/cccc-stock-gets-pre-market-boost-on-roche-tie-up-to-develop-cancer-treatments/cZJWd7GRIrY
0 · Reply
NasdaqPulse
NasdaqPulse Apr. 7 at 1:15 PM
$ABBV joining TrumpRx and the stock is still fading — market not impressed. 👉Click to view @NasdaqPulse for timely updates amid the volatility. $ABBV at $206.69, down 1% today, sitting well below all key MAs. SMA20 at $214.34, SMA50 at $221.37 — both acting as overhead resistance. RSI at 37.92, approaching oversold but no floor yet. Down 11% this month alone. $RHHBY in the same boat. TrumpRx catalyst isn't moving the needle. Watching for a bounce near 52W low support zone or a flush toward $195. No reason to catch this knife early.
0 · Reply
scotttrader213
scotttrader213 Apr. 7 at 11:32 AM
$RHHBY $ABBE AbbVie (ABBV) and Roche’s (RHHBY) Genentech unit have become the latest drugmakers to offer their medicines on TrumpRx, a government-run direct-to-consumer platform launched earlier this year, according to CBS News.
0 · Reply
DonCorleone77
DonCorleone77 Apr. 6 at 11:26 PM
$ABBV $RHHBY AbbVie, Genentech to sell popular commercial drugs on TrumpRx, CBS says AbbVie (ABBV) and Roche's (RHHBY) Genentech will be the two latest drug makers to officially begin selling popular commercial medications on the White House's TrumpRx pharmaceutical site as soon as Monday, CBS News' Olivia Rinaldi reports. AbbVie, which reached a deal with the White House earlier this year to lower the cost of certain drugs, will sell Humira on the platform at an 86% discount, while Genentech's Xofluza will be priced at around $50, down from $168, on TrumpRx, the author notes, citing a Whit House official.
0 · Reply
trenddetector
trenddetector Apr. 3 at 4:13 PM
$RHHBY Built a free tool to help navigate cancer treatment options and clinical trials — would really appreciate feedback https://nimble-frangollo-81ff5e.netlify.app/
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 3 at 2:49 PM
$OMER again show me another pre clinical to fda approved never had a reverse split. Just got 240 million upfront cash follow up up to 2.1 billion. Ceo is a legend Double surgeon orthopedic stanford and duke pages of medical patent. Dude is overqualified for life. Alien 👽 👾 https://patents.justia.com/inventor/thomas-dudler $RGC $PFE $RHHBY
1 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 2 at 4:53 PM
$OMER is domestic doesn't apply if you don't have a drug to sell. $NVO $HIMS $RHHBY Commercial distribution and sales of YARTEMLEA began in January 2026. Both adult and pediatric patients with TA-TMA are now receiving YARTEMLEA, including patients who have recently failed prior off-label C5- and C3-inhibitor regimens, in both hospital and outpatient settings. We are commercializing YARTEMLEA in the U.S. market and have deployed our field force of account managers and directors, market development managers, access leads, and medical science liaisons to engage directly with transplant centers across the United States.
0 · Reply
scotttrader213
scotttrader213 Apr. 1 at 2:53 PM
$RHHBY nice comeback as it moves higher once again
0 · Reply
Quantumup
Quantumup Apr. 1 at 12:57 PM
BofA⬆️ $SRRK's PT to $58 from $51 and reiterated at a Buy rating. $RHHBY LLY NVO PTCT IONS - $BIIB BofA said in its note—SRRK announced resubmission of its BLA for apitegromab (api) in spinal muscular atrophy following a positive Type C meeting on Mar 3. With FDA alignment, two fill-finish partners are included in the filing with the company expecting a late-Sept PDUFA goal date for the Class II re-filing. We view applying with two mfg options for US approval to be highly encouraging as it de-risks the sole approvability issue cited in the 2025 CRL for api. Based on this update, we update our US launch timeline to 4Q26 from mid-27 and reiterate our Buy rating with higher $58 PO (see model changes inside).
0 · Reply